Vericel Corporation or Galapagos NV: Who Leads in Yearly Revenue?

Biotech Revenue Battle: Galapagos NV vs. Vericel Corporation

__timestamp	Galapagos NV	Vericel Corporation
Wednesday, January 1, 2014	69368000	28796000
Thursday, January 1, 2015	39563000	51168000
Friday, January 1, 2016	129517000	54383000
Sunday, January 1, 2017	127087000	63924000
Monday, January 1, 2018	288836000	90857000
Tuesday, January 1, 2019	844986000	117850000
Wednesday, January 1, 2020	478053000	124179000
Friday, January 1, 2021	484846000	156184000
Saturday, January 1, 2022	505280000	164365000
Sunday, January 1, 2023	239724000	197516000

Igniting the spark of knowledge

Vericel Corporation vs. Galapagos NV: A Revenue Showdown

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Galapagos NV and Vericel Corporation have been vying for dominance. From 2014 to 2023, Galapagos NV consistently outperformed Vericel in revenue, peaking in 2019 with a staggering 844% increase from its 2014 figures. However, the tide began to shift in 2023, with Vericel closing the gap, achieving a 585% growth since 2014. This trend suggests a potential shift in market leadership. While Galapagos NV's revenue saw a decline in 2023, Vericel's steady growth trajectory indicates its rising prominence. As the biotech industry evolves, these companies' strategic decisions will be crucial in determining their future standings.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025